We are live on ! Find out more
SCM

Soleus Capital Management Portfolio holdings

AUM $2.47B
1-Year Est. Return 115.63%
This Fund
S&P 500
This Quarter Est. Return
+2.63%
1 Year Est. Return
+115.63%
3 Year Est. Return
+435.52%
5 Year Est. Return
+604.31%
10 Year Est. Return
–
AUM
$2.47B
AUM Growth
-$242M
Cap. Flow
-$190M
Cap. Flow %
-7.68%
Top 10 Hldgs %
50.34%
Holding
119
New
24
Increased
30
Reduced
30
Closed
26

Top Buys

Rank Stock Value
1
PODD icon
Insulet
PODD
+$104M
2
VCEL icon
Vericel Corp
VCEL
+$63.4M
3
UTHR icon
United Therapeutics
UTHR
+$63.3M
4
KRYS icon
Krystal Biotech
KRYS
+$56.4M
5
PGNY icon
Progyny
PGNY
+$44.3M

Top Sells

Rank Stock Value
1
DXCM icon
DexCom
DXCM
+$80.6M
2
FOLD
Amicus Therapeutics
FOLD
+$74.2M
3
CELC icon
Celcuity
CELC
+$57.1M
4
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$39M
5
GSK icon
GSK
GSK
+$31.3M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MSLE
76
Satellos Bioscience
MSLE
$178M
$2.33M 0.09%
+414,359
New +$4.07M
ARWR icon
77
Arrowhead Research
ARWR
$10.5B
$1.79M 0.07%
+28,479
New +$1.8M
NSPR icon
78
InspireMD
NSPR
$32.8M
$1.7M 0.07%
1,045,708
-104,292
-9% -$178K
INSM icon
79
Insmed
INSM
$23.5B
$1.68M 0.07%
10,250
-38,250
-79% -$5.88M
CTMX icon
80
CytomX Therapeutics
CTMX
$745M
$1.41M 0.06%
+300,000
New +$1.52M
CGON icon
81
CG Oncology
CGON
$6.33B
$1.35M 0.05%
20,000
-150,000
-88% -$8.5M
NEO icon
82
NeoGenomics
NEO
$1.88B
$1.3M 0.05%
175,000
-252,504
-59% -$2.66M
QNRX
83
Quoin Pharmaceuticals
QNRX
$8.56M
$480K 0.02%
72,730
+47,730
+191% +$432K
COGT icon
84
Cogent Biosciences
COGT
$6.77B
$385K 0.02%
10,000
-110,000
-92% -$4.06M
TYRA icon
85
Tyra Biosciences
TYRA
$1.89B
$383K 0.02%
10,000
-115,000
-92% -$3.72M
STAA icon
86
STAAR Surgical
STAA
$1.21B
$374K 0.02%
20,000
-5,000
-20% -$95.4K
ANAB icon
87
AnaptysBio
ANAB
$1.59B
$333K 0.01%
6,000
-129,000
-96% -$6.94M
RAPP
88
Rapport Therapeutics
RAPP
$2.04B
$313K 0.01%
+10,000
New +$281K
RIGL icon
89
Rigel Pharmaceuticals
RIGL
$727M
$270K 0.01%
10,000
-290,034
-97% -$9.75M
ZYME icon
90
Zymeworks
ZYME
$1.77B
$250K 0.01%
10,000
-90,000
-90% -$2.13M
LBRX
91
LB Pharmaceuticals
LBRX
$927M
$247K 0.01%
10,000
– –
ORKA
92
Oruka Therapeutics
ORKA
$5.69B
$245K 0.01%
5,000
-185,000
-97% -$6.43M
JSPR icon
93
Jasper Therapeutics
JSPR
$25.6M
$242K 0.01%
276,312
+76,312
+38% +$106K
ABVX
94
Abivax
ABVX
$11.7B
– –
-45,000
Closed -$6.07M
ACLX
95
DELISTED
Arcellx
ACLX
– –
-30,000
Closed -$1.96M
BLTE
96
Belite Bio
BLTE
$6.46B
– –
-40,354
Closed -$6.46M
CALC icon
97
CalciMedica
CALC
$11.2M
– –
-683,904
Closed -$4.51M
CAPR icon
98
Capricor Therapeutics
CAPR
$1.15B
– –
-646,390
Closed -$18.7M
CDTX
99
DELISTED
Cidara Therapeutics
CDTX
– –
-38,811
Closed -$8.57M
DCTH icon
100
Delcath Systems
DCTH
$442M
– –
-10,000
Closed -$101K
1 2 3
4
5

Similar funds

TW
Trajan Wealth Scottsdale, Arizona $2.48B AUM 17.44% 1-Year Est. Return
JC
JB Capital Wethersfield, Connecticut $2.48B AUM 22.31% 1-Year Est. Return
M
Mirova Paris, France $2.46B AUM 11.42% 1-Year Est. Return
SG
Sourcerock Group Denver, Colorado $2.48B AUM 72.25% 1-Year Est. Return
BW
BIP Wealth Atlanta, Georgia $2.46B AUM 14.38% 1-Year Est. Return
BL
Balentine LLC Atlanta, Georgia $2.48B AUM 17.44% 1-Year Est. Return
FFA
First Foundation Advisors Irvine, California $2.48B AUM 18.56% 1-Year Est. Return
GWM
Greenwich Wealth Management Greenwich, Connecticut $2.45B AUM 39.53% 1-Year Est. Return

Soleus Capital Management's Q1 2026 Portfolio in Review

As of Q1 2026, Soleus Capital Management held 119 positions worth $2.47B, down 8.9% from $2.71B the previous quarter. Its ten largest holdings account for 50% of the portfolio.

Soleus Capital Management withdrew a net $190M in Q1 2026, closing 26 positions and reducing 30 holdings. Its most notable exit was Amicus Therapeutics, an estimated $74.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 87% a quarter earlier.

Against the trend, Soleus Capital Management opened a new position in Progyny worth $35.1M.

  • Soleus Capital Management's largest Q1 2026 buy was Progyny: 2,067,000 shares worth $35.1M.
  • Soleus Capital Management added most to Insulet in Q1 2026, an estimated $104M increase.
  • Soleus Capital Management's biggest Q1 2026 reduction was DexCom, cutting an estimated $80.6M.
  • Soleus Capital Management fully exited Amicus Therapeutics in Q1 2026, selling an estimated $74.2M.
  • Soleus Capital Management's ten largest holdings make up 50% of its $2.47B portfolio in Q1 2026.
  • Soleus Capital Management opened 24 new positions and closed 26 in Q1 2026.
  • Soleus Capital Management's portfolio value fell 8.9% quarter-over-quarter to $2.47B.

Based on Soleus Capital Management's 13F filing for Q1 2026, filed 14 May 2026.